Last reviewed · How we verify

NCT05688865

Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis

Recruiting now Last updated 10 May 2024
What this trial tests

trial testing urinary markers in Membranous Nephropathy in 50 participants. Currently enrolling.

Timeline
1 February 2023
Primary endpoint
31 December 2024
31 December 2025

Quick facts

Lead sponsorChinese University of Hong Kong
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date1 February 2023
Primary completion31 December 2024
Estimated completion31 December 2025
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Membranous Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the correlation of these urinary biomarkers with the serum sample and evaluated the clinical utility of using urinary sample in the detection and prognostication of MGN. Fifty patients with newly diagnosed biopsy proven MGN would be recruited and followed up for 1 years. Serum and urinary biomarkers would be collected every 4 months and their antibody titres measured with ELISA assay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Membranous Nephropathy

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05688865.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing